Pharmaceutical Technology· GlobalData Healthcare·· 1 天前AI 评分12
ESMO26：GSK 的 Mo-Rez 在拥挤的卵巢癌 ADC 赛道寻求优势
ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
AI 导读
GSK 在 ESMO26 上公布其 ADC 药物 Mo-Rez 的卵巢癌数据，试图在竞争激烈的 ADC 赛道中建立差异化优势。原文未披露具体疗效数据、ORR 或 PFS 等细节。
正文 · 原文
Unlock FREE Access to Premium Content
Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.
With a free Pharmaceutical Technology profile, you can:
- Access exclusive analyst commentary and expert insights
- View premium forecasts and data-driven pharmaceutical industry insights
- Stay up to date with pharma news, manufacturing innovation, and regulatory developments
- Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here
Powered by
来源：Pharmaceutical Technology · pharmaceutical-technology.com